TNFRSF17 and Miyoshi myopathy: While BCMA expression increases significantly with the progression of MM, but the intensity of expression varies greatly from patient to patient (203) potentially affecting the therapeutic benefits, CD38 levels are robust and constant during MM pathogenesis.